Reporter brief
Aging Mammary Stem Cells and Breast Cancer Prevention
What happened
Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This was not a clinical trial in living subjects, so it cannot establish whether rapamycin prevents breast cancer in humans or provides clinical benefit.
- The sample size was not reported, preventing assessment of statistical power or generalizability.
- The specific effect sizes were not reported, limiting ability to judge the magnitude of the reduction in malignant markers or aberrant cells.
Study design and sample
Other; Human.
Surgical specimens (breast tissue)
- Design
- Other
- Sample
- —
- Journal
- LuZhe Sun
- Published
- Dec 5, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.